Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 3

Research Article

Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 3

Histological features of the decompensated PBC-AIH patients.

VariablesUDCA-only group (N=14)UDCA+IS group (N=14)P value

Number of portal areas1090.541
Severe interface hepatitis0/142/140.481
Moderate interface hepatitis14/1412/140.481
Hepatocyte rosette formation8/1410/140.695
Lymphoplasmacytic infiltrate13/1413/14>0.999
Emperipolesis0/140/14-
Bile duct damage13/1410/140.326
Ductopenia9/146/140.449
Bile duct proliferation11/149/140.678
Cholestasis7/146/14>0.999
G0/1/2/3/4 (N)0/0/2/12/00/1/2/7/40.374
S0/1/2/3/4 (N)0/3/4/5/20/0/3/8/30.117

Note. UDCA, ursodeoxycholic acid; IS, immunosuppressants.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.